Structure-based design of δ-lactones for new antifungal drug development: susceptibility, mechanism of action, and toxicity

2019 ◽  
Vol 64 (4) ◽  
pp. 509-519 ◽  
Author(s):  
Daiane F. Dalla Lana ◽  
Ânderson R. Carvalho ◽  
William Lopes ◽  
Marilene H. Vainstein ◽  
Luciano S. P. Guimarães ◽  
...  
Keyword(s):  
Drug Development ◽  
Mechanism Of Action ◽  
Antifungal Drug

NEW ORIGINAL DRUG ROSEOFUNGIN-AS, OINTMENT 2%

2021 ◽  
pp. 55-64
Author(s):  
А.К. САДАНОВ ◽  
В.Э. БЕРЕЗИН ◽  
И.Р. КУЛМАГАМБЕТОВ ◽  
Л.П. ТРЕНОЖНИКОВА ◽  
А.С. БАЛГИМБАЕВА
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Physicochemical Properties ◽  
Phase I ◽  
Mechanism Of Action ◽  
Chemical Structure ◽  
Antifungal Drug ◽  
Polyene Antibiotic

В статье приводятся сведения о разработке нового отечественного противогрибкового препарата «Розеофунгин-АС, мазь 2%» для наружного применения на основе оригинального природного полиенового антибиотика розеофунгина. Приводятся данные о продуценте антибиотика, процессе его биосинтеза и получения, его физико-химических свойствах и химической структуре, рассматриваются его антифунгальные и антивирусные свойства, механизм его действия, а также основные этапы разработки противогрибкового препарата - доклинические и I, II и III фазы клинических исследований. This paper provides the information on the development of new domestic antifungal drug Roseofungin-AS, ointment 2% for external use based on the original natural polyene antibiotic roseofungin. Data on the antibiotic producer, the process of its biosynthesis and production, its physicochemical properties and chemical structure are presented, its antifungal and antiviral properties, the mechanism of action as well as the main stages of the antifungal drug development including preclinical and phase I, II, III clinical trials are discussed.

scholarly journals Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway

2020 ◽  
Vol 6 (3) ◽  
pp. 142
Author(s):  
Kyle McEvoy ◽  
Tyler G. Normile ◽  
Maurizio Del Poeta
Keyword(s):  
Drug Resistance ◽  
Drug Development ◽  
Mechanism Of Action ◽  
Fungal Infections ◽  
Antifungal Drugs ◽  
Antifungal Drug ◽  
Antifungal Compounds ◽  
Metabolizing Enzymes ◽  
Progressive Development

Fungal infections are becoming more prevalent and problematic due to the continual rise of immune deficient patients as well as the progressive development of drug resistance towards currently available antifungal drugs. There has been a significant increase in the development of antifungal compounds with a similar mechanism of action of current drugs. In contrast, there has been very little progress in developing compounds inhibiting totally new fungal targets or/and fungal pathways. This review focuses on novel compounds recently discovered to target the fungal sphingolipids and their metabolizing enzymes.

Past, Present, and Future of Antifungal Drug Development

2016 ◽  
pp. 125-167 ◽  
Author(s):  
P. K. Shukla ◽  
Pratiksha Singh ◽  
Ravindra Kumar Yadav ◽  
Smriti Pandey ◽  
Shome S. Bhunia
Keyword(s):  
Drug Development ◽  
Antifungal Drug

scholarly journals The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database

2021 ◽  
Author(s):  
Pascal Johann ◽  
Dominic Lenz ◽  
Markus Ries
Keyword(s):  
Drug Development ◽  
Orphan Drug ◽  
Mechanism Of Action ◽  
Drug Product ◽  
Treatment Options ◽  
Orphan Drugs ◽  
Cross Sectional ◽  
Therapeutic Mechanism ◽  
Development Pipeline ◽  
Insight Into

Abstract Background: Glioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are still dismal. An insight into the current drug development pipeline for GBM is therefore of particular interest. Objectives: To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat GBM. Methods: Quantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan Drug Product database between 1983 and 2020. STROBE criteria were respected. Results: Four orphan drugs out of 161 (2,4%) orphan drug designations were approved for the treatment for GBM by the FDA between 1983 and 2020. Fourteen orphan drug designations were subsequently withdrawn for unknown reasons. The number of orphan drug designations per year shows a growing trend. In the last decade, the therapeutic mechanism of action of designated compounds intended to treat glioblastoma shifted from cytotoxic drugs (median year of designation 2008) to immunotherapeutic approaches and small molecules (median year of designation 2014 and 2015 respectively) suggesting an increased focus on precision in the therapeutic mechanism of action for compounds the development pipeline. Conclusion: Despite the fact that current pharmacological treatment options in GBM are sparse, the drug development pipeline is steadily growing. In particular, the surge of designated immunotherapies detected in the last years raises the hope that elaborate combination possibilities between classical therapeutic backbones (radiotherapy) and novel, currently experimental therapeutics may help to provide better therapies for this deadly disease in the future.

scholarly journals The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0252924
Author(s):  
Pascal Johann ◽  
Dominic Lenz ◽  
Markus Ries
Keyword(s):  
Drug Development ◽  
Orphan Drug ◽  
Mechanism Of Action ◽  
Drug Product ◽  
Treatment Options ◽  
Orphan Drugs ◽  
Cross Sectional ◽  
Therapeutic Mechanism ◽  
Development Pipeline ◽  
Insight Into

Background Glioblastoma (GBM) is the most common malignant brain tumour among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are still dismal. An insight into the current drug development pipeline for GBM is therefore of particular interest. Objectives To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat GBM. Methods Quantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan Drug Product database between 1983 and 2020. STROBE criteria were respected. Results Four orphan drugs out of 161 (2,4%) orphan drug designations were approved for the treatment for GBM by the FDA between 1983 and 2020. Fourteen orphan drug designations were subsequently withdrawn for unknown reasons. The number of orphan drug designations per year shows a growing trend. In the last decade, the therapeutic mechanism of action of designated compounds intended to treat glioblastoma shifted from cytotoxic drugs (median year of designation 2008) to immunotherapeutic approaches and small molecules (median year of designation 2014 and 2015 respectively) suggesting an increased focus on precision in the therapeutic mechanism of action for compounds the development pipeline. Conclusion Despite the fact that current pharmacological treatment options in GBM are sparse, the drug development pipeline is steadily growing. In particular, the surge of designated immunotherapies detected in the last years raises the hope that elaborate combination possibilities between classical therapeutic backbones (radiotherapy and chemotherapy) and novel, currently experimental therapeutics may help to provide better therapies for this deadly disease in the future.

Sign in / Sign up

Export Citation Format

Share Document